A case of hydroxyurea-induced leg ulcer after definitive treatment suspension in a patient affected by thrombocythemia: effectiveness of a new collagenase.

Abstract

Hydroxyurea (HU) is an antitumor agent effective in the treatment of myeloproliferative disorders. It is usually well-tolerated and has low toxicity but its use is associated with several adverse cutaneous effects. Among them, leg ulcers have been noted in association with long-term administration. Poor response to traditional local and systemic therapy is a typical feature of HU-induced leg ulcers, and discontinuation of the drug is often required to achieve complete wound healing. We present a case of circumferential HU-induced leg ulcer in a patient affected by essential thrombocythemia, in which the lesion occured after the definitive suspension of the treatment. We propose a conservative management with a new collagenase (Bionect Start®) for skin lesions in this type of patient, for whom a surgical treatment could be more complicated, due to the underlying disease.

• Authors: Paolo Fioramonti, Pasquale Fino, Paola Parisi, Nicolo Scuderi, Maria G Onesti
• Journal: In vivo (Athens, Greece) (In Vivo) 2012 Nov-Dec Vol. 26 Issue 6 Pg. 1053-6 ISSN: 1791-7549 [Electronic] Greece
• PMID: 23160693 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Collagenases
• Hydroxyurea

Topics

• Aged
• Antineoplastic Agents (administration & dosage, adverse effects)
• Collagenases (administration & dosage)
• Female
• Humans
• Hydroxyurea (administration & dosage, adverse effects)
• Leg Ulcer (chemically induced, drug therapy, physiopathology)
• Thrombocytosis (drug therapy)
• Wound Healing